Medpace Holdings, Inc. reported significant financial growth in its latest quarterly results, with net revenue reaching $707.3 million for the three months ended June 30, 2026, a 17.2% increase from $603.3 million in the same period last year. For the first half of 2026, revenue rose by 21.7% to $1.414 billion, compared to $1.162 billion in the prior year. The company's net income also saw a substantial increase, climbing to $121.4 million for the second quarter, up from $90.3 million in 2025, and $245.2 million for the six months, compared to $204.9 million in the previous year.

The increase in revenue was primarily driven by growth in the Metabolic, Oncology, Central Nervous System, and Antiviral therapeutic areas. Total direct costs rose to $505.7 million for the second quarter, up from $423.3 million, largely due to higher reimbursed out-of-pocket expenses and increased personnel costs. Selling, general, and administrative expenses increased slightly to $48.1 million for the quarter, while decreasing to $96.0 million for the six months, reflecting a reduction in stock-based compensation expenses.

Operationally, Medpace expanded its workforce to approximately 6,500 employees across 46 countries as of June 30, 2026, supporting its global clinical research services. The company reported a backlog of $3.014 billion, a 4.9% increase from $2.874 billion a year earlier, indicating strong future revenue potential. The company also executed a share repurchase program, buying back 705,616 shares for $294.7 million during the quarter, with a remaining authorization of $527 million.

Looking ahead, Medpace anticipates continued growth driven by its strategic focus on expanding its service offerings and geographic reach. The company plans to invest in operational growth, including capital expenditures and potential acquisitions, while maintaining a strong liquidity position with $502.7 million in cash and cash equivalents as of June 30, 2026. The management remains optimistic about the company's ability to generate sufficient cash flow to support its ongoing operations and strategic initiatives.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service Phase I-IV clinical development services to the biotech, pharmaceutical, and medical device industries. Focused on therapeutic areas like Oncology, CNS, and Cardiovascular, it supports drug development through trial management, regulatory guidance, data sciences, and laboratory services. Its business model emphasizes quality, efficiency, and deep therapeutic expertise to serve small and mid-sized biopharma companies worldwide.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov